Cargando…
Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options
Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disease with a highly variable phenotypic expression, ranging from asymptomatic to drug refractory heart failure (HF) presentation. Pharmacological therapy is the first line of treatment, but options are currently limited to nons...
Autores principales: | Stătescu, Cristian, Enachi, Ștefana, Ureche, Carina, Țăpoi, Laura, Anghel, Larisa, Șalaru, Delia, Pleșoianu, Carmen, Bostan, Mădălina, Marcu, Dragoș, Ovanez Balasanian, Mircea, Sascău, Radu Andy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268685/ https://www.ncbi.nlm.nih.gov/pubmed/34281272 http://dx.doi.org/10.3390/ijms22137218 |
Ejemplares similares
-
Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience
por: Marcu, Dragoș Traian Marius, et al.
Publicado: (2022) -
Cardiac Resynchronization Therapy in Non-Ischemic Cardiomyopathy: Role of Multimodality Imaging
por: Stătescu, Cristian, et al.
Publicado: (2021) -
Uric Acid—An Emergent Risk Marker for Thrombosis?
por: Țăpoi, Laura, et al.
Publicado: (2021) -
The Importance of Multimodality Imaging in the Diagnosis and Management of Patients with Infiltrative Cardiomyopathies: An Update
por: Sascău, Radu, et al.
Publicado: (2021) -
An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy
por: Tudurachi, Bogdan-Sorin, et al.
Publicado: (2023)